DealSep 03, 2026
Deal — What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal?▸
medium impact
DealSep 01, 2026
Deal — Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong?▸
medium impact
ReadoutAug 31, 2026
Clinical data — Eli Lilly To Acquire Merida And Pay Up To $2.875B In Cash; Transaction Expected To Close In Q4 2026▸
medium impact
ApprovalAug 31, 2026
FDA approval — Eli Lilly (LLY) Stock May Be 30% Undervalued Despite Fresh FDA Approval▸
high impact
DealAug 31, 2026
Deal — Lilly Is Bigger Than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.▸
medium impact
ApprovalAug 28, 2026
FDA approval — Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardi…▸
high impact
DealAug 19, 2026
Deal — Amplitude Therapeutics Partners With Eli Lilly Over Discovery, Development Of taRNA Vaccine Candidates For Infectious D…▸
medium impact
DealAug 17, 2026
Deal — OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Recei…▸
medium impact
ReadoutAug 12, 2026
Clinical data — Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation▸
medium impact
DealAug 07, 2026
Deal — Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’▸
medium impact
ReadoutAug 07, 2026
Clinical data — These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks▸
medium impact
EarningsAug 05, 2026
Q2 2026 report+5.3%positive
EarningsApr 30, 2026
Q1 2026 report+5.8%positive
EarningsFeb 04, 2026
FY 2025 report-5.6%negative
EarningsOct 30, 2025
Q3 2025 report+7.4%positive
EarningsAug 07, 2025
Q2 2025 report-0.2%muted
EarningsMay 01, 2025
Q1 2025 report-2.4%muted
EarningsFeb 06, 2025
FY 2024 report-0.6%muted
EarningsJan 14, 2025
FY 2024 report-2.6%muted
EarningsOct 30, 2024
Q3 2024 report-4.8%negative